About the pneumococcal AMC

in page functions

The pneumococcal Advance Market Commitment is an innovative way to make effective and affordable pneumococcal vaccines available for children in developing countries

Nicaragua 2010

Each year, pneumococcal disease takes the lives of half million children under five years of age, making it the leading vaccine-preventable cause of death among young children.

The most effective way to prevent these deaths is to ensure access to effective, safe and affordable vaccines.

The pneumococcal Advance Market Commitment (AMC) is designed to protect children against pneumococcal disease.

Through donor commitments, this innovative funding mechanism incentivises vaccine makers to produce suitable and affordable vaccines for the world's poorest countries. These countries are then able to plan for immunisation programmes knowing that vaccines will be available rapidly, in the quantities they need and at affordable prices.

It is estimated that the pilot can prevent more than 1.5 million childhood deaths by 2020.


The overarching goal of the pilot AMC is to reduce morbidity and mortality from pneumococcal diseases. The pneumococcal AMC is designed to:

  • accelerate the development of vaccines that meet developing country needs;
  • bring forward the availability of effective pneumococcal vaccines - through scaling up of production capacity to meet developing country vaccine demand;
  • accelerate vaccine uptake - through predictable vaccine pricing for countries and manufacturers;
  • test the AMC concept for potential future applications.

Why does the AMC target pneumococcal disease?

The decision about which disease to target was made by an independent expert committee. The committee included members from both developing and industrial countries with expertise in public health, epidemiology, industry economics, vaccine development and law.

Which pneumococcal vaccine?

Minimum product specification for the pneumococcal vaccine were developed by WHO. These are called the target product profile (TPP) and relate to the public health impact and suitability of the product, covering measures of vaccine efficacy, safety, dose-scheduling, presentation and packaging, and represent the minimally acceptable standard a vaccine needs to meet in order to be eligible for AMC support.

Full marks for Kenya's pneumococcal rollout

The success of Kenya's pneumococcal vaccine rollout depends to a large extent on the ability of Eunice Wanjiku Njabu and her fellow national health workers to administer the vaccine.

Read more

Kenya pneumococcal launch health worker

US$ 1 = US$ 18

A study in Health Affairs covering 73 Gavi-supported countries over the 2011–2020 period shows that, for every US$ 1 spent on immunisation, US$ 18 are saved in healthcare costs, lost wages and lost productivity due to illness. If we take into account the broader benefits of people living longer, healthier lives, the return on investment rises to US$ 48 per US$ 1 spent.

Ozawa S, Clark S, Portnoy A et al. Return on investment from childhood immunizations in low- and middle-income countries, 2011-20, Health Affairs 2016

More facts...

close icon

modal window here